Intellia Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $26.1M | $16.5M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $67.6M | $31.8M |
| SG&A Expense | $28.0M | $16.8M |
| Operating Income | $-69.6M | $-32.2M |
| Operating Margin | -266.3% | -195.2% |
| Interest Expense | — | — |
| Pretax Income | $-67.5M | $-31.6M |
| Income Tax Expense | — | $0 |
| Net Income | $-67.5M | $-31.6M |
| Net Margin | -258.6% | -192.0% |
| EPS (Basic) | $-1.88 | $-1.42 |
| EPS (Diluted) | $-1.88 | $-1.42 |
| Shares Outstanding (Basic) | 42.4M | 36.0M |
| Shares Outstanding (Diluted) | 42.4M | 36.0M |
| Dividends Per Share | — | — |